GRAF FINCKENSTEIN FRIEDRICH 4
4 · IOVANCE BIOTHERAPEUTICS, INC. · Filed Sep 4, 2025
Insider Transaction Report
Form 4
GRAF FINCKENSTEIN FRIEDRICH
Chief Medical Officer
Transactions
- Exercise/Conversion
Common Stock
2025-09-02+12,697→ 111,857 total - Exercise/Conversion
Restricted Stock Units
2025-09-02−3,907→ 7,813 total→ Common stock (3,907 underlying) - Exercise/Conversion
Restricted Stock Units
2025-09-02−8,790→ 52,738 total→ Common stock (8,790 underlying) - Tax Payment
Common Stock
2025-09-02$2.19/sh−6,448$14,121→ 105,409 total
Footnotes (7)
- [F1]Represents such shares underlying the restricted stock units ("RSUs") which vested on the transaction date.
- [F2]Represents shares withheld by the Issuer to satisfy the mandatory tax withholding requirements upon vesting of the RSUs. This is not an open market sale of securities.
- [F3]Represents the common stock remaining after deducting the common stock withheld for taxes.
- [F4]Each RSU represents a contingent right to receive one share of the Issuer's common stock.
- [F5]The remaining RSUs will vest in equal quarterly installments.
- [F6]Such aggregate number reflects the remainder of such RSUs granted on March 2, 2023, but does not include any other RSUs held by such Reporting Person.
- [F7]Such aggregate number reflects the remainder of such RSUs granted on March 1, 2024, but does not include any other RSUs held by such Reporting Person.